MTMasato Takahashi

Masato Takahashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masato Takahashi has a total of 378 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study

    by S. Saji, T. Yamashita, J. Tsurutani, Y. Sagara, H. Shigematsu, T. Takano, M. Takahashi, K. Araki, N. Tamura, M. Tsuneizumi, et al.

  • Open Access

    Cytokine release syndrome induced by neoadjuvant pembrolizumab in early triple-negative breast cancer: a case report with implications for early diagnosis and management

    by Hiroki Haneda, Tomohiro Oshino, Hinata Mori, Rumi Niwa, Karin Shikishima, Dong Li, Yumi Moriya, Sayuri Kuwahara, Nana Yoshida, Mitsuchika Hosoda, et al.

    Introducition: Cytokine release syndrome (CRS) is a rare but potentially severe immune-related adverse event (irAE) associated with immune checkpoint inhibitor (ICI) therapy. CRS is characterized by high fever, hemodynamic instability, and potential multi-organ dysfunction. Pembrolizumab, an ICI, is increasingly used as standard perioperative treatment for triple-negative breast cancer (TNBC). However, reports on CRS in TNBC remain scarce. Case presentation: We report the case of a 63-year-old woman diagnosed with TNBC (T3N2M0, Stage IIIA) who received pembrolizumab plus chemotherapy. On day 1 of the third cycle, she developed a high fever and headache within hours of pembrolizumab administration. On day 2, hypotension, tachypnea, hypoxia, and liver and renal dysfunction were observed. Suspecting CRS, the patient was admitted to the intensive care unit (ICU) and treated with tocilizumab and steroid pulse therapy, relusting in rapid clinical improvement. On day 4, the patient was discharged from the ICU. She was started on oral prednisolone with gradual tapering; however, she experienced CRS recurrence. The patient underwent surgery rather than resuming chemotherapy. At 20 months postoperatively, neither breast cancer relapse nor CRS recurrence was observed. Conclusion: Early diagnosis and treatment of CRS are crucial to prevent severe multi-organ failure.


  • Open Access

    Thermal ablation as a minimally invasive alternative to surgery for primary breast cancer: a review

    by Masato Takahashi, Takayuki Kinoshita, Eisuke Fukuma

    Recent diagnostic advances have facilitated a transition from invasive surgery toward minimally invasive interventions for early breast cancer. Although breast-conserving surgery (BCS) remains the standard treatment, it can result in postoperative breast deformities and a low cosmetic satisfaction in some patients. Breast cancer patients increasingly demand surgical treatments that ensure robust oncological control while simultaneously preserving breast cosmesis. Minimally invasive local treatments, especially thermal ablation techniques such as cryoablation (CRYO) and radiofrequency ablation (RFA), have been developed as potential alternatives to surgery. Thermal ablation has emerged as a modality offering local control rates comparable to traditional surgery. In 2023, RFA for early breast cancer was approved for coverage under the Japanese Ministry of Health, Labour, and Welfare insurance system, and has been implemented as a treatment performed by surgeons. This review highlights the principles, clinical outcomes, and the evolving role of the surgeon, who must transcend being a mere “operator” to master these techniques as essential therapeutic options within their surgical repertoire. CRYO induces tumor cell death through rapid freezing and thawing, whereas RFA applies frictional heat to achieve coagulative necrosis. Phase II studies, such as ACOSOG Z1072 and ICE3, have demonstrated complete ablation rates of 92% and low recurrence rates in small, low-risk tumors. The RAFAELO study reported a 5-year ipsilateral breast tumor-free survival rate of 98.6%, forming the basis for insurance approval for RFA in Japan. Both modalities offer shorter procedure times, minimal scarring, and superior cosmetic outcomes compared to BCS. The Japan Breast Cancer Society instituted an operator accreditation system to ensure procedural quality and safety. Thermal ablation achieves favorable local control with excellent cosmetic results in selected patients with small localized breast cancers. Surgeons must integrate these techniques into multidisciplinary care through refined clinical decision-making processes. As diagnostic advances increase the detection of small tumors, thermal ablation could become an alternative standard to BCS, reducing surgical invasiveness and improving the quality of life for patients with early breast cancer.

  • Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial

    by Yosuke Aoyama, Kosuke Kashiwabara, Yuichiro Kikawa, Naruto Taira, Hirofumi Mukai, Masato Takahashi

  • Open Access

    Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study

    by Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando, Takashi Yamanaka, Hideo Shigematsu, Masato Takahashi, Shigenori E. Nagai, Mitsuya Ito, Tomoyuki Aruga, Mariko Tokiwa, et al.

    To investigate long-term outcomes for triple‑negative breast cancer (TNBC) patients enrolled in JBCRG-22. TNBC (cT1c-T3, cN0-1, M0) patients were stratified by homologous recombination deficiency (HRD) and germline BRCA mutation (gBRCAm) status. Group A patients (aged < 65 years with HRD-positive tumors, or those with gBRCAm, if available) were randomized to receive 4 cycles of weekly paclitaxel (group A1) or eribulin (group A2), both with carboplatin, followed by 4 cycles of anthracycline. Group B patients (aged < 65 years with HRD-negative tumors or aged ≥ 65 years) were randomized to receive 6 cycles of eribulin plus cyclophosphamide (group B1) or eribulin plus capecitabine (group B2). Five-year invasive disease-free survival (IDFS), distant disease-free survival (DDFS), and overall survival (OS) were assessed. Additionally, data were analyzed by biomarker levels including lymphocyte count (LC) and neutrophil-to-lymphocyte ratio (NLR). Ninety-nine patients were followed for a median of 5.6 years. In patients who received eribulin-based therapy (groups A2 + B1 + B2), 5-year IDFS and OS rates, respectively, were 95% and 100% in patients who achieved pCR after neoadjuvant therapy (n = 20) and 71.4% and 80.2% in those who did not (n = 56), showing significantly better prognosis in the pCR cohort (p < 0.05). OS tended to be better in patients with baseline LC ≥ 1500/mm3 and NLR < 3, particularly in eribulin-treated patients, although differences were non-significant. These findings will help guide the development of eribulin-based neoadjuvant chemotherapy for selected TNBC patients. Our exploratory analysis of LC and NLR results may help inform clinical prediction models for eribulin-treated patients. The study has been registered with the University Hospital Medical Information Network Clinical Trials Registry ( https://www.umin.ac.jp/ctr/index-j.htm ) with unique trial number UMIN000023162. The Japan Breast Cancer Research Group trial number is JBCRG-22.


  • Open Access

    Pembrolizumab for Early‐Stage Triple‐Negative Breast Cancer: KEYNOTE ‐522 Japan Subgroup Analysis

    by Masato Takahashi, Hirofumi Mukai, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Mitsuya Itoh, Junichiro Watanabe, Yuko Tanabe, Naohito Yamamoto, Yasuo Miyoshi, et al.

    The phase 3 KEYNOTE‐522 study in high‐risk early‐stage triple‐negative breast cancer (TNBC) showed significantly improved efficacy outcomes with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab versus neoadjuvant chemotherapy alone. We present findings from the KEYNOTE‐522 Japan subgroup. Eligible participants (aged ≥ 18 years) with untreated locally advanced TNBC (stage T1c N1–2 or T2–4 N0–2) were randomized 2:1 to neoadjuvant pembrolizumab 200 mg or placebo plus chemotherapy every 3 weeks for 8 cycles followed by surgery and adjuvant pembrolizumab or placebo for ≤ 9 cycles. Primary endpoints were pathologic complete response (pCR; ypT0/Tis ypN0) at the time of surgery and event‐free survival (EFS). Of 76 participants enrolled in Japan, 45 were randomized to the pembrolizumab arm and 31 to the placebo arm. Median time from randomization to data cutoff (March 22, 2024) was 76.3 months. Twenty‐four participants (53%) in the pembrolizumab arm and 15 (48%) in the placebo arm achieved pCR (between‐treatment arm difference, 4.9%; 95% CI, −17.6% to 27.1%); findings were similar regardless of PD‐L1 expression. Rates of EFS at 60 months were 84% and 73%, respectively (HR, 0.54; 95% CI, 0.20–1.50). Grade 3 or 4 treatment‐related AEs occurred in 37 of 45 participants (82%) treated with pembrolizumab and 23 of 30 participants (77%) treated with placebo; there were no grade 5 AEs. In conclusion, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed improved efficacy outcomes and manageable safety versus neoadjuvant chemotherapy alone in Japanese participants, supporting the use of this regimen in Japanese patients with high‐risk early‐stage TNBC. Trial Registration: The study ( ClinicalTrials.gov , NCT03036488) was conducted in compliance with local and/or national regulations and International Council for Harmonization Good Clinical Practice guidelines and in accordance with the ethical principles originating from the Declaration of Helsinki


  • Open Access

    Impact of breast tumor size discrepancy between contrast-enhanced and conventional ultrasonography on axillary node metastasis: a retrospective cohort study

    by Tomohiro Oshino, Hirokazu Shimizu, Megumi Sato, Mutsumi Nishida, Tatsunori Horie, Satonori Tsuneta, Fumi Kato, Mitsuchika Hosoda, Isao Yokota, Kohsuke Kudo, et al.

    Background: Conventional ultrasonography (cUS) and contrast-enhanced ultrasonography (CEUS) are used to evaluate breast cancer tumors and axillary lymph nodes (ALN), by which the treatment strategy for breast cancer is determined. A breast tumor size discrepancy on CEUS compared with cUS is often observed, for which the reasons are unclear. We hypothesized that this discrepancy reflects the metastatic potential, and this study investigated the association between size discrepancies on cUS and CEUS in relation to ALN metastasis in breast cancer. Methods: This retrospective study enrolled 259 patients who underwent surgery for breast cancer after preoperative cUS and CEUS examinations. Patients were grouped into a DISCR (i.e., tumor size discrepancy ≥ 4.0 mm between CEUS and cUS measurements) and non-DISCR group. The primary outcome was ALN metastasis, defined by pathological evaluation. Secondary outcomes were the 5-year recurrence-free survival rates. Results: There were 94 patients in the DISCR and 165 in the non-DISCR groups. No tumor size differences measured by cUS were observed between two groups ( p = 0.82), whereas the DISCR group had a significantly higher rate of ALN metastasis ( p < 0.01). Multivariate analyses showed a discrepancy of ≥ 4.0 mm was a risk for ALN metastasis (odds ratio: 5.838, 95% confidence interval [CI]: 2.408–14.155). The 5-year recurrence-free survival rate was lower in the DISCR (0.750, 95% CI: 0.632–0.868) than in the non-DISCR (0.924, 95% CI; 0.870–0.978) group. Conclusion: An increase in contrast-enhanced ultrasonography tumor size is helpful for assessing axillary lymph node metastasis and prognosis.

  • Open Access

    Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis

    by Masato Takahashi, Hiroyuki Yasojima, Tomofumi Osako, Kenichi Inoue, Masahiro Kawashima, Hideki Maeda, Mitsuya Ito, Yasuaki Sagara, Kan Yonemori, Masaya Hattori, et al.

    Background: An open-label, single-arm, multicenter Japanese phase 2 study (J-Ph2) found first-line palbociclib plus letrozole to be effective and tolerable in postmenopausal Japanese women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) advanced breast cancer (ABC), but overall survival (OS) data were immature. Here, we report the final analysis of a follow-up study of J-Ph2 evaluating OS and subsequent therapy. Methods: Patients ( N = 42) who participated in J-Ph2 were included in this follow-up study. Primary endpoint was OS; other endpoints included chemotherapy-free survival (CFS) and type and duration of subsequent therapy. Median OS, CFS, and duration of subsequent therapy were estimated using the Kaplan–Meier method; outcomes were stratified by baseline demographic, disease characteristics, and type of second-line therapies. Results: At median follow up of 101.0 months, median OS was 85.4 months (95% CI, 64.3–not estimable) and median CFS was 69.1 months (95% CI, 24.2–85.4). Eighty-one percent of patients (34/42) received a second-line therapy; of those, 85.3% (29/34) received endocrine-based therapy and 8.8% (3/34) received chemotherapy. Median duration of second-line therapy was 7.6 months. Sixty-nine percent of patients (29/42) received a third-line therapy; of those, 58.6% (17/29) received endocrine-based therapy and 31.0% (9/29) received chemotherapy; median duration of third-line therapy was 6.0 months. Conclusion: This analysis showed a median OS of > 7 years with first-line palbociclib plus letrozole in Japanese patients with ER+/HER2– ABC. Patient demographics, disease characteristics, and subsequent therapy decisions may have contributed to the extended median OS observed in this study. Clinical trial registration: ClinicalTrials.gov, NCT04735367.

  • Open Access

    Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

    by Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, et al.

    In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)–positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months. Patients who have previously received pertuzumab-containing regimens as first-/second-line treatment for LA/mBC were randomly assigned 1:1 to two groups, PTC group (n = 110) and TC group (n = 109). Median OS was longer in the PTC group (median OS 36.2 v 26.5 months; hazard ratio [HR], 0.73 [one side 95% CI upper limit, 0.97]). Updated median investigator-assessed PFS (5.5 v 4.2 months; HR, 0.81 [one side 95% CI upper limit, 1.02]) were also better in the PTC group. Median PFS by independent review did not show the difference between the two groups (4.4 v 4.4 months; HR, 1.03 [one side 95% CI upper limit, 1.36]). These findings suggest that dual HER2 blockade with pertuzumab plus trastuzumab could contribute to improving OS in patients who have previously been treated with pertuzumab-containing regimens for HER2-positive LA/mBC.


  • Open Access

    Analysis of the conditions for applying BRCA genetic testing to women with breast cancer using the Japanese HBOC consortium and the Japanese organization of hereditary breast and ovarian cancer (JOHBOC) registry project database

    by Masato Takahashi, Yuko Minoura, Hiroki Den, Tadashi Nomizu, Takanori Ishida, Hiraku Kumamaru, Masami Arai, Seigo Nakamura

    Background: Considering past research in Europe and the USA, the conditions for medical insurance coverage of BRCA1/2 genetic testing (GT) in Japan have been established as follows: 1. Breast cancer onset at 45 years or younger age; 2. Triple-negative breast cancer (TNBC) onset at 60 years or younger age; 3. Onset of two or more primary breast cancers; 4. Family history of breast cancer, ovarian cancer, or pancreatic cancer up to the third degree; 5. Male breast cancer, 6. Ovarian, fallopian, or peritoneal cancers. However, data to determine the importance and extent of each factor in the current conditions are insufficient. Consequently, this study aimed to assess the validity of insurance coverage conditions in Japan, elucidate the relationship between these conditions, and explore the possibility of proposing new indicators. Methods: A total of 5987 breast cancer patients were enrolled from 92 centers participating in the HBOC consortium and the JOHBOC registry project. Of these, 5904 patients were analyzed after excluding 48 male breast cancer patients due to insufficient numbers for analysis and 35 patients whose age at breast cancer onset was unknown or unregistered. We compared 1,091 cases in which pathogenic variants (PVs) (BRCA1(B1s): 543, BRCA2(B2s): 548) were detected with 4580 cases in which no variants (non-Vs) were detected. Variants of uncertain significance (VUS: 233 cases) were not classified as either PVs or non-Vs for subsequent analysis. We investigated the validity of each condition under which an HBOC diagnosis could be considered for medical insurance coverage. Results: Regardless of the insurance coverage conditions, the detection rate of pathogenic variants (DRPV) of all analyzed cases was 19.2%. The DRPV under the insurance coverage conditions for GT—‘Age of breast cancer onset ≤ 45 years,’ ‘TNBC onset at ≤ 60 years,’ ‘ ≥ 2 primary breast cancers,’ ‘Patients with breast cancer concurrent with ovarian cancer,’ and ‘ ≥ 1 family history of breast or ovarian cancer up to the third degree’—was 25.4%, 31.6%, 24.6%, 48.8%, and 25.6%, respectively. Those within the insurance coverage group showed a pathogenic variant detection rate of 21.1%, compared to only 5.6% outside of the coverage. Our analysis indicates that medical insurance coverage conditions effectively identify candidates for GT. Furthermore, when examining the number of conditions met and the positivity rate, the positivity rate was 11.2%, with only one condition met. This rate increases exponentially as more conditions are met, underscoring the importance of multiple matching conditions. Additionally, those with comorbid ovarian cancer or a family history of ovarian cancer are more likely to have a pathogenic variant. Additionally, we reevaluated cases who did not meet the medical insurance conditions. TNBC occurrence was significantly associated with B1s, even when restricted to onset age ≥ 61 years. Familial history of prostate cancer also significantly associated with B2s. Conclusion: This study determined that the Japanese medical insurance coverage conditions effectively identified candidates eligible for GT. Consequently, it is imperative to disseminate information to all patients with breast cancer covered by insurance, emphasizing the opportunity for GT, particularly if they have ovarian cancer complications or a family history of ovarian cancer.